Key Takeaways:
- China's NMPA approves Andewei and Fukewei for soft part sarcoma.
- This is the fourth indication for the combination therapy.
- Approval expands the company's oncology drug market.
戻る
Sino Biopharmaceutical wins 4th approval for cancer drug combo
Sino Biopharmaceutical (1177.HK) received its fourth marketing approval from Chinese regulators for its combination cancer therapy, expanding its use for a rare and aggressive sarcoma.
The National Medical Products Administration (NMPA) approved the treatment, which combines the PD-L1 inhibitor Beimu Subai (Andewei) with the tyrosine kinase inhibitor Anlotinib (Fukewei), for advanced or unresectable alveolar soft part sarcoma (ASPS), the company said in a statement.
This marks the fifth approved indication for Andewei and the eleventh for Fukewei, a small-molecule drug. The combination therapy is developed by Chia Tai Tianqing Pharmaceutical, a subsidiary of Sino Biopharmaceutical.
The approval strengthens Sino Biopharmaceutical's position in the oncology market, a key growth driver for the company. The expanded label for the two drugs could lead to a significant increase in their addressable patient population and contribute to future revenue growth.
The approval for ASPS, a rare and difficult-to-treat cancer, underscores the efficacy of the combination therapy. Investors will watch for the company's next earnings report to gauge the initial sales impact of this new indication.
This article is for informational purposes only and does not constitute investment advice.
